or rapid FPA generation (>1 pmol/ ml per min) (33 patients). Slow FPA generation was found in 10/10 patients with venous thrombosis, in 4/4 with aortic aneurysm, and in several patients with acquired hypofibrinogenemia. In one such patient, addition of fibrinogen resulted in rapid FPA generation whereas thrombin addition was without effect. Rapid FPA generation was generally linear, was usually associated with slower fibrinopeptide B generation and was inhibited by parenteral or in vitro heparin. It is thought to reflect increased thrombin activity and was seen in patients with pulmonary embolism, active systemic lupus erythematosus, renal transplant rejection, and after infusion of prothrombin concentrates. The initial rate of FPA cleavage by thrombin at fibrinogen concentrations from 0.05 to 4 mg/ml showed little change between 2 and 4 mg/ml with a Km of 2.99 ,uM. At a fibrinogen concentration of 2.5 mg/ml the FPA cleavage rate was 49.2±+1.6 nmol/ml per min per U of thrombin. Exogenous thrombin added to normal blood generated 21.7 nmol/ml per U of Dr.
cubated in the collecting syringe for different time periods before addition to heparin and Trasylol, and the rate of in vitro generation of FPA was calculated as the mean increment in FPA concentration per minute over the linear portion of the generation curve. 36 normal individuals had a mean plasma FPA level of 0.64±0.56 pmol/ml and an FPA generation rate of <0.5 pmol/ml per min. Clinical samples with elevated plasma FPA levels manifested slow (<1 pmol/ml per min) (28 patients) or rapid FPA generation (>1 pmol/ ml per min) (33 patients). Slow FPA generation was found in 10/10 patients with venous thrombosis, in 4/4 with aortic aneurysm, and in several patients with acquired hypofibrinogenemia. In one such patient, addition of fibrinogen resulted in rapid FPA generation whereas thrombin addition was without effect. Rapid FPA generation was generally linear, was usually associated with slower fibrinopeptide B generation and was inhibited by parenteral or in vitro heparin. It is thought to reflect increased thrombin activity and was seen in patients with pulmonary embolism, active systemic lupus erythematosus, renal transplant rejection, and after infusion of prothrombin concentrates. The initial rate of FPA cleavage by thrombin at fibrinogen concentrations from 0.05 to 4 mg/ml showed little change between 2 and 4 mg/ml with a Km of 2.99 ,uM. At a fibrinogen concentration of 2.5 mg/ml INTRODUCTION Thrombin specifically cleaves fibrinopeptides A and B (FPA and FPB)l from fibrinogen to initiate blood clotting (1) . Teger-Nilsson demonstrated the presence of the fibrinopeptides chemically in the blood of dogs infused with thrombin (2) . The development ofa radioimmunoassay (3) has permitted measurement of FPA levels in clinical blood samples as an index ofthrombin action in vivo (4) (5) (6) (7) (8) (9) . A radioimmunoassay for FPB has also been developed and together with the FPA assay, used to measure the relative cleavage rates of small fibrinopeptide containing fractions from fibrinogen by different enzymes in buffer solutions (10) .
In the present paper the rate of in vitro generation of FPA was studied by measuring plasma FPA levels in blood incubated in the collecting syringe. At 1-min intervals for a total of 4 min aliquots of blood were mixed with heparin and Trasylol. The plasma FPA level was then measured and generation rates were obtained by expressing FPA levels as a function of incubation time. In patients with elevated FPA levels, two different patterns of FPA generation in vitro have been distinguished; a relatively low rate 'Abbreviations used in this paper: FPA, fibrinopeptide A; FPB, fibrinopeptide B.
of generation (<1 pmol/ml per min) and a relatively high rate (>1 pmol/ml per min). Evidence will be presented to indicate that a relatively high rate of FPA generation is due to thrombin activity in the blood.
METHODS
Native fibrinopeptides A and B prepared as described by Blomback et al. were used as standards throughout these studies (11) . Preparation of the antisera to the fibrinopeptides has been previously described (3, 4, 10 The FPA radioimmunoassay was performed as previously described (4 (18 ml), the needle was withdrawn from the vein and removed from the syringe. The blood in the syringe was mixed by inversion and 4.5 ml blood was added at 1-min intervals to each of four tubes containing 0.5 ml of 0.15 M NaCl solution with 500 U of heparin and 500 U of Trasylol. The plasma was then processed as described above and the fibrinopeptide levels were measured. When FPA generation was tested in blood collected in two syringes, a 19-gauge butterfly needle was inserted into a vein, a 35-ml polyethylene syringe was attached, and 18 ml of blood was withdrawn and processed as described above. As soon as the first syringe was withdrawn from the needle the second syringe was attached, and a further 18 ml of blood was collected and treated in exactly the same way as the first 18 ml of blood. The influence of added fibrinogen on fibrinopeptide generation was tested by pipetting 2 ml of fibrinogen solution (5 mg/ml) into a blood collection syringe and collecting 18 ml of blood into the syringe in the usual manner. The fibrinogen and blood were mixed thoroughly and the generation rate of fibrinopeptides was determined. The influence of exogenous thrombin on fibrinopeptide generation was tested as for fibrinogen except that a thrombin solution in Tris-buffered saline with 0.1% ovalbumin was pipetted into the syringe in place of fibrinogen.
The effect of EDTA on the in vitro generation of FPA was tested by measuring plasma FPA levels in each of four tubes of blood. Tubes 1 and 2 contained 0.5 ml of 0.15 M NaCl with 500 U of heparin and 500 U of Trasylol. Tube 3 contained 0.5 ml of 0.15 M NaCl with 500 U of heparin, 500 U of Trasylol, and 5 ,ug of EDTA. Tube 4 contained 250 ,ul of 0.15 M NaCl with 5 ,ug of EDTA. 18 ml of blood was collected, and 4.5 ml was rapidly (within 1 min) added to tubes 1, 3, and 4, the contents of which were mixed by inversion. At 3 min, 4.5 ml of blood was added to tube 2, and 0.25 ml of 0.15 M NaCl with 500 U of heparin and 500 U of Trasylol was added to tube 4 and mixed. The blood in each tube was then processed and assayed for FPA content. The protocol for this experiment is given in the legend to Fig. 3 .
Two individuals collected all the blood samples, and the interval between the first entry of the blood into the syringe and the mixing of the blood with the anti-coagulant mixture was timed with a stopwatch. This time was less than 50 s. If the blood did not flow freely, a fresh sample was collected. Care was taken to avoid drawing blood from patients who were receiving intravenous infusions. Although in normal individuals an intravenous needle was not associated with a detectable increment in the plasma FPA level in blood drawn from the opposite arm, blood drawn through the intravenous needle did have an elevated plasma FPA level.
FPA generation in the clinical blood samples was generally linear or in some instances accelerating at 4 min, and the rate of FPA generation in vitro in the syringe was calculated by averaging the mean of the generation rates per 15 .0-ml conical polypropylene centrifuge tubes in a waterbath (Eberbach Corp., Ann Arbor, Mich.) at 37°C. 100 ,A of thrombin (1 X 10-5 to 2 x 10-2U) was added to each tube, the contents of which were thoroughly mixed. At intervals, 50 /1d of hirudin (1 U/ml in saline) was added to each tube, the contents were mixed and placed in an ice-bath, and 1 The partial thromboplastin time, prothrombin time, and thrombin time were measured as previously described (14); fibrinogen was measured by the Ellis anclStransky (15) and Ratnoff and Menzie (16) methods. Serum was-prepared and fibrinogen antigen was measured by the tanned erythrocyte hemagglutination inhibition test as described by Merskey et al. (17) .
For control purposes, blood was obtained from normal, healthy laboratory personnel and student donors. The patients studied were all examined by a single physician (Dr. M. Ti) participating in this study. This physician followed each patient during the hospital course. After discharge, the overall record was reviewed by three physicians to assign a final diagnosis. The principal evidence for pulmonary embolism was radiological assessment of lung scans with radiolabeled macroaggregated albumin and chest X ray as well as the hospital course and response to heparin therapy. The remaining studies concem patients with elevated plasma FPA levels. These patients were divided into groups depending on whether the FPA generation rate was less than or greater than 1 pmol/ml per min. In 28 patients, the FPA generation rate was < 1 pmol/ ml per min (Table Ib, Figs. la and 2). The diseases for which this pattern was consistent were thrombophlebitis (10/10) and aortic aneurysm (4/4). All of the patients studied with the exception of those listed in Table II had normal or elevated fibrinogen levels. The coagulation findings in five patients thought to have excessive intravascular coagulation were examined in more detail (Table II) (Table III) . Patient IV3 generated significant FPB immunoreactivity in vitro. 33 patients with elevated plasma FPA levels (mean 9.2 pmol/ml) had relatively rapid FPA generation (>1 pmol/ml per min) Figs. lb and 2, and Table  IV) . To test the postulate that in vitro FPA release resulted from thrombin action, FPA and FPB cleavage (10) . In 17 patients the generation of FPA was significantly greater than that of FPB (Table V) . In two patients (nos. 10 and 12) generation of FPB was more rapid than that of FPA. Further evidence consistent with FPA cleavage in the blood samples being due to thrombin is the reduction of plasma FPA levels to the normal range and virtual abolition of in vitro FPA generation after 1 day of heparin therapy (Table  VI) . Addition ofheparin in vitro significantly decreased in vitro FPA generation (Fig. 3) . EDTA added in vitro did not affect the initial plasma FPA level but reduced in vitro FPA generation in normals and in patients with elevated FPA levels (Fig. 3) . FPA generation in the presence of EDTA decreased with time and was nonlinear (Fig. lc) . The effect of thrombin on FPA generation in normal blood was examined. The FPA generation pattern was nonlinear, and FPA levels were constant between 3 and 4 min (Fig. 4) . In the 1st min after addition of thrombin, 21.7 nmol FPA were cleaved per ml/U of thrombin. Initial FPA cleavage rates from fibrinogen by thrombin were studied at varying fibrinogen concentrations. There was relatively little change in cleavage rate at fibrinogen concentrations of 2-4 mg/ml (Fig. 5) . The Michaelis constant (Kin) calculated from this data was 2.99 ,mM. When the fibrinogen concentration was 2.5 mg/ml the rate of FPA cleavage was proportional to the thrombin concentration. The rate was calculated to be 49.2+ 1.6 nmol FPA/ml per min per U of thrombin (Fig. 6 ). When the clinical findings are considered, the mean plasma FPA level in 24 normal individuals was 0.64 pmol/ml (0.07-1.2) which is somewhat higher than our previous finding of 0.36 pmol/ml (0.07-1.3) (4); the discrepancy is thought to result from the lack of correction for incomplete FPA extraction from the blood in our previous study, whereas in the present study the levels represent complete FPA recovery. The (2) Post-proplex infusion (20) .
The rapid FPA generation pattern was investigated further. In 17 of 19 patients, FPA generation was more rapid than FPB generation, consistent with thrombin action; however, in 2 patients, FPB generation was more rapid, suggesting the action of another enzyme, possibly plasmin (10). The reduction in FPA level and generation rate after parenteral heparin is also consistent with thrombin action (Table VI) . Heparin added to blood in vitro markedly decreased FPA generation (Fig. 3) (Fig. 3) . Balanced formation and inactivation of thrombin in the circulating blood would imply the presence of prothrombin activator in the blood.
On the basis of these findings, it is postulated that the blood of certain patients contains elevated (Fig. 6 ). When thrombin was added to whole blood the amount of FPA generated in the 1st min was 21.7 nmol/min per U of thrombin (Fig. 4) .
The lesser activity of thrombin in whole blood pre- sumably reflects the effect of inhibitors (antithrombin [22, 23] and a-2-macroglobuilin [24, 25] ) and alternate suibstrates. These findings raise many questions which require further studies for resolution. Among the questions are: What is the specificity of the different FPA generation patterns in patients with different diseases? Can the presence of circulating thrombin antigen as distinct from activity be demonstrated by immunological techniques (23) ? Are activated coagulation intermediates present in the blood of patients with certain diseases?
